RT Journal Article
SR Electronic
T1 Prehospital activation of the cardiac catheterisation laboratory in ST-segment elevation myocardial infarction (STEMI) for primary percutaneous coronary intervention (PCI)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.16.23290073
DO 10.1101/2023.05.16.23290073
A1 Savage, Michael L
A1 Hay, Karen
A1 Volbon, William
A1 Doan, Tan
A1 Murdoch J, Dale
A1 Hammett, Christopher
A1 Poulter, Rohan
A1 Walters, Darren L
A1 Denman, Russell
A1 Ranasinghe, Isuru
A1 Raffel, Owen Christopher
YR 2023
UL http://medrxiv.org/content/early/2023/05/17/2023.05.16.23290073.abstract
AB Background Prehospital activation of the cardiac catheter laboratory is associated with significant improvements in ST-segment elevation myocardial infarction (STEMI) performance measures. However, there is equivocal data, particularly within Australia regarding its influence on mortality. We assessed the association of prehospital activation on performance measures and mortality in STEMI patients treated with primary percutaneous coronary intervention (PCI) from the Queensland Cardiac Outcomes Registry (QCOR).Methods Consecutive ambulance transported STEMI patients treated with primary PCI were analysed from 1st January 2017 to 31st December 2020 from the QCOR. The total and direct effects of prehospital activation on the primary outcomes (30-day and 1-year cardiovascular mortality) were estimated using logistic regression analyses. Secondary outcomes were STEMI performance measures.Results Among 2498 patients (mean age: 62.2 ± 12.4 years; 79.2% male), 73% underwent prehospital activation. Median door-to-balloon (DTB) time (34mins [26-46] vs 86 mins [68-113]; p<0.001), first-electrocardiograph-to-balloon (ECGTB) time (83.5 mins [72-98] vs 109 mins [81-139]; p<0.001), and proportion of patients meeting STEMI targets (DTB<60mins 90% vs 16%; p<0.001), ECGTB<90mins (62% vs 33%; p<0.001) were significantly improved with prehospital activation. Prehospital activation was associated with significantly lower 30-day (1.6% vs 6.6%; p<0.001) and 1-year cardiovascular mortality (2.9% vs 9.5%; p<0.001). After adjustment, no prehospital activation was strongly associated with increased 30-day (OR: 3.6; 95%CI: 2.2-6.0, p<0.001) and 1-year cardiovascular mortality (OR: 3.0 (95%CI:2.0-4.6; p<0.001).Conclusions Prehospital activation of cardiac catheterisation laboratory for primary PCI was associated with significantly shorter time to reperfusion, achievement of STEMI performance measures and lower 30-day and 1-year cardiovascular mortality.Clinical PerspectiveIn patients who suffer STEMI, prehospital activation of the cardiac catheter laboratory and initiation of medical therapy is associated with shorter time to reperfusion, greater achievement of performance measures and lower cardiovascular mortalityThis study adds to the existing literature and demonstrates that a standardised prehospital activation strategy can be implemented on a large scaleWidespread implementation of standardised prehospital activation strategies may offer opportunity to expedite STEMI care and improve outcomesCompeting Interest StatementThe authors have declared no competing interest.Clinical Trialn/aFunding StatementNil FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Human Research Ethics Committee of the Prince Charles Hospital (LNR/2020/TPCH/75136).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe clinical data used to support the findings of this study are restricted by the Prince Charles Hospital Human research and ethics committee in order to protect patient privacy and confidentiality. Data are available from the relevant Prince Charles data custodian/s for researchers who meet the criteria for access to confidential data.